Journal of Liver Cancer最新文献_第10页

Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy. 经动脉放射栓塞和多种酪氨酸激酶抑制剂治疗晚期肝细胞癌成功。

Journal of Liver Cancer Pub Date : 2020-09-01 DOI: 10.17998/jlc.20.2.160

Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik

{"title":"Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy.","authors":"Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik","doi":"10.17998/jlc.20.2.160","DOIUrl":"https://doi.org/10.17998/jlc.20.2.160","url":null,"abstract":"Transarterial radioembolization (TARE) with yttrium-90 microspheres has become widely utilized in managing hepatocellular carcinoma (HCC). The utility of TARE is expanding with new insights through experiences from real-world practice and clinical trials, and recently published data suggest that TARE in combination with sorafenib may improve the overall survival in selected patients. Here, we report a case of advanced stage HCC that was successfully treated with TARE and sorafenib. The patient achieved complete response (CR) at 12 months after the initial treatment with TARE and sorafenib, followed by additional transarterial chemoembolization and proton beam therapy for local tumor recurrence at 19-month post-TARE. The patient was followed up every 3 months thereafter and still achieved CR both biochemically and radiologically for the following 12 months. A combination strategy of TARE and systemic therapy may be a useful alternative treatment option for selected patients with advanced stage HCC.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"20 2","pages":"160-166"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/af/65/jlc-20-2-160.PMC10035672.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9728086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation. 一名肝移植后复发性肝癌患者索拉非尼治疗失败后，瑞非尼序贯治疗成功。

Journal of Liver Cancer Pub Date : 2020-03-01 DOI: 10.17998/jlc.20.1.84

Soon Kyu Lee, Jeong Won Jang, Heechul Nam, Pil Soo Sung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon

{"title":"Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation.","authors":"Soon Kyu Lee, Jeong Won Jang, Heechul Nam, Pil Soo Sung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon","doi":"10.17998/jlc.20.1.84","DOIUrl":"https://doi.org/10.17998/jlc.20.1.84","url":null,"abstract":"The efficacy and safety of sequential systemic therapy for the treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) are not well established. This study describes a successful experience where sequential therapy with sorafenib followed by regorafenib was used to treat recurrent HCC in a 54-year old male LT recipient. After HCC recurred in both lungs 10 months after LT, sorafenib was administered with radiation therapy to treat pulmonary metastases. However, after 4 months of sorafenib treatment showed progressive pulmonary metastases, sequential regorafenib treatment was started. After 3 months (cycles) of regorafenib treatment, tumor response was partial, and after 6 months (cycles), disease status remained stable without signs of progression or drug-related serious adverse events. This case suggests that sequential systemic therapy is feasible in patient with recurrent HCC after LT.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"20 1","pages":"84-89"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/4b/jlc-20-1-84.PMC10035698.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9735372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gut-microbiome Taxonomic Profiling as Non-invasive Biomarkers for the Early Detection of Alcoholic Hepatocellular Carcinoma. 肠道微生物组分类分析作为酒精性肝细胞癌早期检测的非侵入性生物标志物

Journal of Liver Cancer Pub Date : 2020-03-01 DOI: 10.17998/jlc.20.1.32

Jun Seok, Ki Tae Suk

{"title":"Gut-microbiome Taxonomic Profiling as Non-invasive Biomarkers for the Early Detection of Alcoholic Hepatocellular Carcinoma.","authors":"Jun Seok, Ki Tae Suk","doi":"10.17998/jlc.20.1.32","DOIUrl":"https://doi.org/10.17998/jlc.20.1.32","url":null,"abstract":"Background/aims: Hepatocellular carcinoma (HCC) is a prevalent form of primary liver cancer and the fifth leading cause of worldwide cancer mortality. Though early diagnosis of HCC is important, so far lack of effective biomarkers for early diagnosis of HCC has been a problem. In this study, we searched for potential functional biomarkers of alcoholic HCC by using metagenomics approach.Methods: Between September 2017 and April 2019, normal control (n=44), alcoholic liver cirrhosis (n=44), and alcoholic HCC (n=13) groups were prospectively enrolled and analyzed. Gut microbiota was analyzed using the 16S-based microbiome taxonomic profiling platform of EzBioCloud Apps and analyzing system.Results: There was a statistically significant difference among groups in diversity (P<0.05). In the comparison of phylum between cirrhosis and HCC, Proteobacteria were increased and Bacteroidetes were decreased. Firmicutes were not significantly different among the three groups. In the taxonomic profiling, relative abundance of Lactobacillus in the cirrhosis and HCC groups showed richness (P<0.05). In the biomarker analysis between cirrhosis and HCC, obiquinome Fe-S protein 3, global nitrogen regulator, Vesicle-associated membrane protein 7, toxin YoeB, peroxisome-assembly ATPase, and nitrogen oxide reductase regulator were differently expressed (P<0.001).Conclusions: Alcoholic HCC showed different expressions in the stool taxonomy and biomarker compared with that of cirrhosis and control. Therefore, new biomarkers using stool analysis for alcoholic HCC are necessary.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"20 1","pages":"32-40"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/c3/jlc-20-1-32.PMC10035701.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9735373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance. 肝磁共振成像在肝细胞癌监测中的应用。

Journal of Liver Cancer Pub Date : 2020-03-01 DOI: 10.17998/jlc.20.1.25

So Hyun Park, Bohyun Kim

引用次数: 6

Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma. 破译和逆转免疫抑制细胞在肝细胞癌治疗中的作用。

Journal of Liver Cancer Pub Date : 2020-03-01 DOI: 10.17998/jlc.20.1.1

Su Jong Yu, Tim F Greten

{"title":"Deciphering and Reversing Immunosuppressive Cells in the Treatment of Hepatocellular Carcinoma.","authors":"Su Jong Yu, Tim F Greten","doi":"10.17998/jlc.20.1.1","DOIUrl":"https://doi.org/10.17998/jlc.20.1.1","url":null,"abstract":"Use of immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC) has been partially successful. However, most HCC patients do not respond to immunotherapy. HCC has been shown to induce several immune suppressor mechanisms in patients. These suppressor mechanisms include involvement of myeloid-derived suppressor cells, regulatory T-cells, functionally impaired dendritic cells (DCs), neutrophils, monocytes, and tumor associated macrophages. The accumulation of immunosuppressive cells may lead to an immunosuppressive tumor microenvironment as well as the dense fibrotic stroma which may contribute to immune tolerance. Our laboratory has been investigating different cellular mechanisms of immune suppression in HCC patients. In vitro as well as in vivo studies have demonstrated that abrogation of the suppressor cells enhances or unmasks tumor-specific antitumor immune responses. Two or three effective systemic therapies including ICIs and/or molecular targeted therapies and the addition of innovative combination therapies targeting immune suppressor cells may lead to increased immune recognition with a greater tumor response. We reviewed the literature for the latest research on immune suppressor cells in HCC, and here we provide a comprehensive summary of the recent studies in this field.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"20 1","pages":"1-16"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/53/jlc-20-1-1.PMC10035699.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9735371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Recurrent Coronary Artery Vasospasm in a Patient with Hepatocellular Carcinoma Treated with Sorafenib: a Case Report and Literature Review. 索拉非尼治疗肝细胞癌患者复发性冠状动脉血管痉挛1例报告及文献复习。

Journal of Liver Cancer Pub Date : 2020-03-01 DOI: 10.17998/jlc.20.1.67

Dae Hyun Lim, Jai Hoon Yoon, Dae Won Jun, Oh Young Lee, Byung Chul Yoon, Hang Rak Lee, Kyung Soo Kim, Ho Soon Choi

引用次数: 0

Combined Transarterial Chemoembolization and External Beam Radiotherapy in a Patient with Recurrent Huge Hepatocellular Carcinoma after Hepatic Resection. 经动脉化疗栓塞联合外束放疗治疗肝切除术后复发大肝癌1例。

Journal of Liver Cancer Pub Date : 2020-03-01 DOI: 10.17998/jlc.20.1.90

Jesang Yu, Jinhong Jung, Sang Min Yoon

引用次数: 0

Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors. 肝细胞癌的组织病理学变异:根据世界卫生组织消化系统肿瘤分类第5版的更新。

Journal of Liver Cancer Pub Date : 2020-03-01 DOI: 10.17998/jlc.20.1.17

Haeryoung Kim, Mi Jang, Young Nyun Park

引用次数: 24

A Survey of Liver Cancer Specialists' Views on the National Liver Cancer Screening Program in Korea. 韩国肝癌专家对全国肝癌筛查计划的看法调查

Journal of Liver Cancer Pub Date : 2020-03-01 DOI: 10.17998/jlc.20.1.53

Won Sohn, Young-Sun Lee, Jae Geun Lee, Jihyun An, Eun Sun Jang, Dong Ho Lee, Dong Hyun Sinn

{"title":"A Survey of Liver Cancer Specialists' Views on the National Liver Cancer Screening Program in Korea.","authors":"Won Sohn, Young-Sun Lee, Jae Geun Lee, Jihyun An, Eun Sun Jang, Dong Ho Lee, Dong Hyun Sinn","doi":"10.17998/jlc.20.1.53","DOIUrl":"https://doi.org/10.17998/jlc.20.1.53","url":null,"abstract":"Background/aims: To reduce the cancer burden, the Korean government initiated the National Cancer Control Plan including the National Liver Cancer Screening Program (NLCSP). Ultrasonography examinations and α-fetoprotein tests at six-month intervals are currently offered for high-risk individuals. High-risk individuals are identified by reviewing the National Health Insurance Service claims data for medical use for the past two years using International Classification of Diseases Codes for specific liver disease. We surveyed the attitudes and opinions towards the NLCSP to understand the issues surrounding the NLCSP in Korea.Methods: Altogether, 90 Korean Liver Cancer Association members participated in online and offline surveys between November and December 2019.Results: Approximately one-quarter (27%) of the survey participants rated the NLCSP as very contributing and about two-thirds (68%) as contributing to some extent toward reducing hepatocellular carcinoma (HCC)-related deaths in Korea. Most (87.8%) responded that the current process of identifying high-risk individuals needs improvement. Many (78.9%) were concerned that the current process identifies individuals who use medical services and paradoxically misses those who do not. When asked for the foremost priority for improvement, solving 'duplication issues between the NLCSP and private clinic HCC screening practices' was the most commonly selected choice (23.3%).Conclusions: The survey participants positively rated the role of the NLCSP in reducing liver cancer deaths. However, many participants rated the NCLSP as needing improvement in all areas. This survey can be a relevant resource for future health policy decisions regarding the NLCSP in Korea.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"20 1","pages":"53-59"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/3c/jlc-20-1-53.PMC10035697.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9735369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Lipiodol Pneumonitis Following Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. 肝细胞癌经导管动脉化疗栓塞后脂醇性肺炎。

Journal of Liver Cancer Pub Date : 2020-03-01 DOI: 10.17998/jlc.20.1.60

Sungkeun Kim, Hee Yeon Kim, Su Lim Lee, Young Mi Ku, Yoo Dong Won, Chang Wook Kim

{"title":"Lipiodol Pneumonitis Following Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.","authors":"Sungkeun Kim, Hee Yeon Kim, Su Lim Lee, Young Mi Ku, Yoo Dong Won, Chang Wook Kim","doi":"10.17998/jlc.20.1.60","DOIUrl":"https://doi.org/10.17998/jlc.20.1.60","url":null,"abstract":"Transcatheter arterial chemoembolization (TACE) is a useful palliative therapeutic modality for hepatocellular carcinoma (HCC). Postembolization syndromes, such as fever, abdominal pain, and elevated liver enzyme levels are commonly known complications of TACE. One post-TACE pulmonary complication, lipiodol pneumonitis, is rarely reported. Lipiodol pneumonitis after TACE appears to be associated with chemical injury due to accidental perfusion of lipiodol to the lung vasculature, promoted by arteriovenous shunts within the hypervascular HCC. Here, we report a 42-year-old man with unresectable HCC and hepatic vein thrombosis. The patient was initially treated with TACE. The following day after TACE, acute respiratory symptoms such as dyspnea and cough developed with decreased oxygen saturation. Chest X-ray and computed tomography showed multiple patches and diffuse ground-glass opacities in both lung fields, suggesting of lipiodol pneumonitis. The patient's condition and radiologic abnormalities subsequently improved after 2 weeks of conservative treatment alone.","PeriodicalId":16226,"journal":{"name":"Journal of Liver Cancer","volume":"20 1","pages":"60-66"},"PeriodicalIF":0.0,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/52/jlc-20-1-60.PMC10035693.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10112914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1